Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Tvardi Therapeutics (TVRD) Receivables - Other (2016 - 2025)

Tvardi Therapeutics' Receivables - Other history spans 11 years, with the latest figure at $1.0 million for Q1 2025.

  • On a quarterly basis, Receivables - Other rose 99.41% to $1.0 million in Q1 2025 year-over-year; TTM through Mar 2025 was $1.0 million, a 99.41% increase, with the full-year FY2024 number at $4.1 million, up 636.58% from a year prior.
  • Receivables - Other hit $1.0 million in Q1 2025 for Tvardi Therapeutics, down from $4.1 million in the prior quarter.
  • Over the last five years, Receivables - Other for TVRD hit a ceiling of $20.3 million in Q3 2021 and a floor of $99000.0 in Q3 2024.
  • Historically, Receivables - Other has averaged $2.4 million across 5 years, with a median of $506000.0 in 2024.
  • Biggest five-year swings in Receivables - Other: skyrocketed 4304.76% in 2021 and later tumbled 97.78% in 2022.
  • Tracing TVRD's Receivables - Other over 5 years: stood at $455000.0 in 2021, then grew by 7.47% to $489000.0 in 2022, then rose by 13.5% to $555000.0 in 2023, then skyrocketed by 636.58% to $4.1 million in 2024, then crashed by 75.32% to $1.0 million in 2025.
  • Business Quant data shows Receivables - Other for TVRD at $1.0 million in Q1 2025, $4.1 million in Q4 2024, and $99000.0 in Q3 2024.